Comparison of exenatide alone or combined with metformin versus metformin in the treatment of polycystic ovaries: a systematic review and meta-analysis

Table 4 The meta-analysis of effectiveness

Outcomes	Comparability of baseline	No. of studies included	No. of cases (T/C)	Heterogeneity test		Meta-analysis results
Outcomes	Comparability of baseline	No. of studies included	No. of cases (T/C)	P	I²	MD/SMD (95% CI)	P value
Comparison between exenatide versus metformin
TT	comparable	4	168/159	0.04	65%	-0.43(-0.84, -0.03)	0.04
SHBG	comparable	4	187/177	0.15	43%	5(3.82,6.18)	< 0.001
FSH	comparable	2	95/83	0.64	0%	0.82(0.41,1.24)	< 0.001
FAI	comparable	4	173/176	0.03	65%	-0.84(-2.69,1.01)	0.38
DHEAS	comparable	4	140/129	0.13	47%	0.03(-0.21,0.27)	0.82
MFR	comparable	2	92/94	< 0.001	97%	0.16(-0.01,0.34)	0.07
HOMA-IR	comparable	5	243/234	0.16	39%	-0.68(-0.84, -0.53)	< 0.001
FINS	comparable	4	229/220	0.82	0%	-0.61(-0.8, -0.42)	< 0.001
FBG	comparable	4	229/220	< 0.001	87%	-0.1(-0.29,0.09)	0.30
Weight	comparable	5	248/251	1	0%	-1.69(-2.49, -0.89)	< 0.001
BMI	comparable	5	248/251	0.03	63%	-1.13(-1.82, -0.43)	0.002
WC	comparable	4	198/201	0.4	0%	-2.49(-3.29, -1.7)	< 0.001
WHR	comparable	3	184/187	0.57	0%	-0.02(-0.03, -0.01)	< 0.001
Comparison between exenatide + metformin and metformin alone
SHBG	comparable	2	64/64	0.41	0%	10.38(6.7,14.06)	< 0.001
FAI	comparable	2	64/64	0.35	0%	-3.34(-4.84, -1.83)	< 0.001
Matsuda index	comparable	2	33/35	0.88	0%	0.21(0.05,0.37)	0.01
Weight	comparable	3	83/85	0.3	17%	-2.32(-3.89, -0.66)	0.006
WC	comparable	2	33/35	0.28	14%	-5.61(-8.4, -2.82)	< 0.001

MFR Menstrual frequency ratio, TT Total testosterone, FSH Follicle stimulating hormone, SHBG Sex hormone binding globulin, LH Luteinizing hormone, DHEAS Dehydroepiandrosterone sulphate, FAI Free androgen index, HOMA-IR Homeostasis model assessment-insulin resistance, FINS Fasting insulin, FBG Fasting blood glucose, BMI Body mass index, WC Waist circumference, WHR Waist-hip ratio

ISSN: 1472-6823